RxDoctor Payments Data

Oliver Horne, MD

Clinical Cardiac Electrophysiology · Macon, GANPI 1053610642

Payments from drug & device makers

$12,184in general payments, 2019–2025

Across 208 payments — averaging $58.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$8K
  • Abbott$933
  • Novartis$560
  • Boston Scientific$433
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$341
  • Biotronik Inc.$278
  • plus $1K from 21 others

What the payments were for

  • Speaking & faculty fees$2,77523%
  • Travel & lodging$3,22226%
  • Food & beverage$6,18651%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,184 in reported general payments places this provider in the 30th percentile of 93 clinical cardiac electrophysiology providers in Georgia.

See all clinical cardiac electrophysiology providers in Georgia

Medicare billing

Part B allowed, 2024
$680,673
Medicare patients
1,326
Services billed
7,776

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban1,374$1,165,158
XareltoRivaroxaban209$204,638
EntrestoSacubitril/Valsartan182$180,898
FarxigaDapagliflozin Propanediol66$50,269
Flecainide Acetate632$27,561
MultaqDronedarone Hcl19$18,343
Dofetilide78$16,107
Metoprolol Succinate1,320$15,430
Pyridostigmine Bromide470$11,949
Amiodarone Hcl811$11,165
VascepaIcosapent Ethyl13$9,471
Mexiletine Hcl119$8,926
Midodrine Hcl162$7,302
Dabigatran EtexilateDabigatran Etexilate Mesylate25$5,821
Diltiazem 12hr ErDiltiazem Hcl25$3,603

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$274$1,165,1581,374 claims
Johnson & JohnsonXarelto$131$204,638209 claims
NovartisEntresto$560$180,898182 claims
AstraZenecaFarxiga$140$50,26966 claims
Sanofi-aventis U.S. LLCMultaq$33$18,34319 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 93 clinical cardiac electrophysiology providers in Georgia.

Other clinical cardiac electrophysiology in Macon

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →